Camber Capital filed an amended 13G on Protalix BioTherapeutics (NYSE:PLX) today disclosing a large increase in its position. Stephen Dubois’ hedge fund had 9 million shares of Protalix at the end of June. The amended filing shows a position of 14.8 million shares corresponding to a 15.59% stake in the company.
You can view the details of this filing here.
More interestingly just before the closing bell Pfizer (NYSE:PFE) also disclosed a large position in the stock which caused the stock to surge as high as $1.24 and close the day at $1.14. This corresponds to a daily gain of 10.7%. Pfizer now owns 5.7% of Protalix’s outstanding shares.
